EU ends first pharmaceutical excessive pricing probe

The European Commission has closed its excessive pricing investigation into Aspen, after the drugmaker committed to reduce the price of six of its cancer medicines and continue supplying them across the EU.


Get unlimited access to all Global Competition Review content